ASCO 2023 — Q&A with Eisai chief medical officer Kirk Shepard

asco-big

As the crowds descend on Chicago for the  annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai (TYO: 4523) chief medical officer Kirk Shepard about his firm’s progress in oncology.

The Japanese company has already outlined the data it plans to unveil, including an oral presentation of overall survival (OS) results from the Phase III CLEAR study.

Eisai is testing its standout product, the multiple kinase (VEGF) blocker Lenvima (lenvatinib), in combination with another heavy hitter, Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical